Gilead Sciences has dedicated around $11 billion so far this year to three acquisitions meant to bolster its pipelines in cancer and immunology. The pharma company, once criticized for making bad deals, hopes it can …
PhRMA head Steve Ubl to step down, according to sources
Stephen Ubl, the leader of the drug industry’s powerful Washington, DC, lobbying group PhRMA, plans to step down, Endpoints News has learned from sources familiar

